ClinicalTrials.gg
CompletedNCT04157751Updated Jul 19, 2022Results posted

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

A Phase 3 interventional study of Empagliflozin and Placebo to Empagliflozin in Heart Failure, sponsored by Boehringer Ingelheim. Completed at 118 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-19.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
530
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing empagliflozin in Heart Failure — 16 open to participants now, 22 under way, 7 of them phase 3. empagliflozin · Heart Failure.

Enrollment
6th of 51
530 · median 90
Started
2020
the only one that year
Phase 3
14 of 51
5 open now
Registered
16th of 51
by date
Lead sponsor
6 of 51
Boehringer Ingelheim

Among the 51 studies testing empagliflozin in Heart Failure, this one is the 6th largest by enrollment, is the only one that started in 2020, is one of 14 in phase 3, and was the 16th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 51 studies testing empagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing empagliflozin in Heart Failure, or all of them as a file.
02

Study summary

This is a study in adults who are in hospital for acute heart failure. The purpose of this study is to find out whether starting to take a medicine called empagliflozin soon after first being treated in hospital helps people with acute heart failure.

Participants are in the study for about 3 months. At the beginning, participants are still in hospital. Later, they visit the hospital about 3 times and get 1 phone call. Participants are put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group takes

1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. It is used to treat type 2 diabetes.

During the study, the doctors check whether participants have additional heart failure events like needing to go to the hospital again because of heart failure. The participants answer questions about how their heart failure affects their life. We then compare the results between the empagliflozin and placebo groups. The doctors also regularly check the general health of the participants.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently hospitalised for the primary diagnosis of acute heart failure (de novo or decompensated chronic HF), regardless of (EF). Patients with a diagnosis of hospitalized heart failure must have HF symptoms at the time of hospital admission
  • Evidence of left ventricular ejection fraction (LVEF, either reduced or preserved EF) as per local reading preferably measured during current hospitalisation or in the 12 months prior to randomisation
  • Patients must be randomised after at least 24 hours and no later than 5 days after admission, as early as possible after stabilization and while still in hospital
  • Patients must fulfil the following stabilisation criteria (while in the hospital):

    • SBP ≥100mm Hg and no symptoms of hypotension in the preceding 6 hours,
    • no increase in i.v. diuretic dose for 6 hours prior to randomisation,
    • no i.v. vasodilators including nitrates within the last 6 hours prior to randomisation
    • no i.v. inotropic drugs for 24 hours prior to randomisation.
  • Elevated NT-proBNP ≥ 1600pg/mL or BNP ≥400 pg/mL according to the local lab, for patients without atrial fibrillation (AF); or elevated NT-proBNP ≥ 2400pg/mL or BNP ≥600 pg/mL for patients with AF, measured during the current hospitalization or in the 72 hours prior to hospital admission,. For patients treated with an angiotensin receptor neprilysin inhibitor (ARNI) in the previous 4 weeks prior to randomisation, only NT-proBNP values should be used
  • HF episode leading to hospitalisation must have been treated with a minimum single dose of 40 mg of i.v. furosemide (or equivalent i.v. loop diuretic defined as 20 mg of torasemide or 1 mg of bumetanide)
  • Further Inclusion Criteria Apply

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock
  • Current hospitalisation for acute heart failure primarily triggered by pulmonary embolism, cerebrovascular accident, or acute myocardial infarction (AMI)
  • Current hospitalisation for acute heart failure not caused primarily by intravascular volume overload;
  • Below interventions in the past 30 days prior to randomisation or planned during the study:

    • Major cardiac surgery, or TAVI (Transcatheter Aortic Valve Implantation), or PCI, or Mitraclip
    • All other surgeries that are considered major according to investigator judgement
    • Implantation of cardiac resynchronisation therapy (CRT) device
    • cardiac mechanical support implantation
    • Carotid artery disease revascularisation (stent or surgery)
  • Acute coronary syndrome / myocardial infarction, stroke or (TIA) in the past 90 days prior to randomisation
  • Heart transplant recipient, or listed for heart transplant with expectation to receive a transplant during the course of this trial (according to investigator judgement), or planned for palliative care for HF, or currently using left ventricular assist device (LVAD) or intra-aortic balloon pump (IABP) or any other type of mechanical circulatory support, or patients on mechanical ventilation, or patients with planned inotropic support in an outpatient setting
  • Haemodynamically significant (severe) uncorrected primary cardiac valvular disease planned for surgery or intervention during the course of the study (note: secondary mitral regurgitation or tricuspid regurgitation due to dilated cardiomyopathy is not excluded unless planned for surgery or intervention during the course of the study)
  • Impaired renal function, defined as \< 20 mL/min/1.73 m2 as measured during hospitalization (latest local lab measurement before randomisation) or requiring dialysis
  • Type 1 Diabetes Mellitus (T1DM)
  • History of ketoacidosis, including diabetic ketoacidosis (DKA)
  • Further Exclusion Criteria Apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
530 participants (actual)

Study arms

  • Experimental
    Empagliflozin

    Drug: Empagliflozin

  • Placebo comparator
    Placebo

    Drug: Placebo to Empagliflozin

Interventions

  • Film-coated tablet

  • DrugPlacebo to Empagliflozin

    Film-coated tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Pairwise Comparisons With Wins of Clinical Benefit, a Composite of Death, Number of Heart Failure Events (HFEs), Time to the First HFE and ≥5-point Difference in CfB in KCCQ-TSS After 90 Days of Treatment

    Clinical benefit, a composite of death, number of HFEs, time to first HFE and change from baseline (CfB) in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) after 90 days of treatment. All patients randomised to empagliflozin are compared to all patients randomised to placebo within strata. For any two patients, a patient will win, i.e. achieve a better clinical outcome, as determined by assessing the following criteria sequentially, stopping when an advantage for either patient is shown: 1. Death: death is worse than no death; earlier death is worse; tied if not possible to determine. 2. Number of HFEs: more HFEs is worse; tied, if same number of HFEs. 3. Time to first HFE: earlier HFE is worse; tied, if not possible to determine. 4. KCCQ-TSS CfB at Day 90: more positive CfB is better; the threshold for the difference is \>= 5 for a win; tied, if difference \< 5. The KCCQ-TSS ranges from 0 to 100, where a higher score reflects a better outcome. pct. = percentage

    Time frame: Up to 90 days. For KCCQ-TSS: at baseline and at day 90.

Secondary outcomes

  1. Number of Participants With Improvement of at Least 10 Points in KCCQ-TSS After 90 Days of Treatment

    Number of participants with improvement of at least 10 points in Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS) from baseline after 90 days of treatment. The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire that includes 23 items that map to 7 domains: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life and self-efficacy. The symptom frequency and symptom burden domains are merged into the total symptom score. Scores are represented on a 0-to-100-point scale, where a higher score reflects a better health status.

    Time frame: At baseline and at day 90.

  2. Change From Baseline in KCCQ-TSS After 90 Days of Treatment

    Change from baseline in Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS). The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire that includes 23 items that map to 7 domains: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life and self-efficacy. The symptom frequency and symptom burden domains are merged into the total symptom score. The score is represented on a 0-to-100-point scale, where a higher score reflects a better health status. Change from baseline in KCCQ-TSS at day 90 was modeled using a MMRM with visit (day 15 and day 30) as repeated measures, adjusted mean (standard error) after 90 days of treatment is reported.

    Time frame: At baseline, at day 15, 30 and at day 90.

  3. Change From Baseline in Log-transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) Area Under the Curve (AUC) Over 30 Days of Treatment

    Change from baseline in log-transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) Area under the curve (AUC) over 30 days of treatment is reported.

    Time frame: From baseline to day 30.

  4. Percentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 30 Days After Initial Hospital Discharge

    The follow-up time for DAOH analyses was defined as 30 days after initial hospital discharge, or time between initial hospital discharge and date of censoring for non-fatal events except for patients who died within the first 30 days, where 30 days was considered as the DAOH follow-up time. DAOH for each patient was calculated as follow-up time subtracted by the number of days in hospital during the 30 days after initial hospital discharge as well as the number of days being dead within the 30 days. Percentage DAOH was defined as DAOH divided by the DAOH follow-up time of each patient multiplied by 100.

    Time frame: Up to 30 days after initial hospital discharge.

  5. Percentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 90 Days After Randomisation

    The follow-up time for DAOH analyses was defined as 90 days after randomisation, or time between randomisation and date of censoring for non-fatal events except for patients who died within the first 90 days, where 90 days was considered as the DAOH follow-up time. DAOH for each patient was calculated as follow-up time subtracted by the number of days in hospital during the 90 days after randomisation as well as the number of days being dead within the first 90 days. Percentage DAOH was defined as DAOH divided by the DAOH follow-up time of each patient multiplied by 100.

    Time frame: Up to 90 days after randomisation.

  6. Incidence Rate of First Occurrence of Cardiovascular (CV) Death or Heart Failure Event (HFE) Until End of Trial Visit

    Incidence rate of first occurrence of CV death or HFE until end of trial visit per 100 patient-year (pt-yrs) at risk is reported. Incidence rate per 100 pt-yrs = 100\* number of patients with event / time at risk \[years\].

    Time frame: Up to 127 days.

  7. Number of Participants With Hospitalization for Heart Failure (HHF) Until 30 Days After Initial Hospital Discharge

    Number of participants with hospitalization for heart failure (HHF) until 30 days after initial hospital discharge.

    Time frame: Up to 30 days after initial hospital discharge.

  8. Composite Renal Endpoint: Number of Participants With Chronic Dialysis, Renal Transplant, Sustained Reduction in eGFR(CKD-EPI)cr

    The occurrence of the composite renal endpoint: * chronic dialysis (with a frequency of twice per week or more for at least 90 days), or * renal transplant, or * sustained reduction in Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) from baseline of ≥40%, or * sustained eGFR \[mL/min/1.73 m2\] \<15 and baseline value ≥30, or * sustained eGFR \<10 and baseline value \<30; is reported by number of participants with component events. (These events may have occurred after the endpoint was already met. Combinations may not have occurred on the same day). Sustained was determined by 2 or more consecutive post-baseline central laboratory measurements separated by at least 30 days.

    Time frame: Up to 90 days.

  9. Weight Change Per Mean Daily Loop Diuretic Dose After 15 Days of Treatment

    Diuretic effect as assessed by weight change per mean daily loop diuretic dose after 15 days of treatment. Diuretic dose = 40 mg intravenous furosemide or 80 mg oral furosemide. Abbreviation: Kg: Kilogram

    Time frame: At baseline and at day 15.

  10. Weight Change Per Mean Daily Loop Diuretic Dose After 30 Days of Treatment

    Diuretic effect as assessed by weight change per mean daily loop diuretic dose after 30 days of treatment. Diuretic dose = 40 mg intravenous furosemide or 80 mg oral furosemide Abbreviation: Kg: Kilogram

    Time frame: At baseline and at day 30.

07

Results

Posted Jun 6, 2022

Participant flow

A multicentre, randomised, double-blind trial to assess whether in-hospital administration of empagliflozin results in improvement in heart failure-related outcomes compared to placebo in patients with acute heart failure.

Participant flow — Overall Study
MilestonePlacebo10 mg Empagliflozin
Started265265
Treated264260
Completed202208
Not completed6357
Withdrew: Withdrawal by subject1217
Withdrew: Lost to follow-up62
Withdrew: Adverse event3423
Withdrew: Not treated15
Withdrew: Other reason not stated above1010

Outcome measures

PrimaryPercentage of Pairwise Comparisons With Wins of Clinical Benefit, a Composite of Death, Number of Heart Failure Events (HFEs), Time to the First HFE and ≥5-point Difference in CfB in KCCQ-TSS After 90 Days of Treatment

Clinical benefit, a composite of death, number of HFEs, time to first HFE and change from baseline (CfB) in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) after 90 days of treatment. All patients randomised to empagliflozin are compared to all patients randomised to placebo within strata. For any two patients, a patient will win, i.e. achieve a better clinical outcome, as determined by assessing the following criteria sequentially, stopping when an advantage for either patient is shown: 1. Death: death is worse than no death; earlier death is worse; tied if not possible to determine. 2. Number of HFEs: more HFEs is worse; tied, if same number of HFEs. 3. Time to first HFE: earlier HFE is worse; tied, if not possible to determine. 4. KCCQ-TSS CfB at Day 90: more positive CfB is better; the threshold for the difference is \>= 5 for a win; tied, if difference \< 5. The KCCQ-TSS ranges from 0 to 100, where a higher score reflects a better outcome. pct. = percentage

Time frame:
Up to 90 days. For KCCQ-TSS: at baseline and at day 90.
Reported as:
Number · pct. (%) of winning pairwise comparisons
Percentage of Pairwise Comparisons With Wins of Clinical Benefit, a Composite of Death, Number of Heart Failure Events (HFEs), Time to the First HFE and ≥5-point Difference in CfB in KCCQ-TSS After 90 Days of Treatment
pct. (%) of winning pairwise comparisonsPlacebo10 mg Empagliflozin
Time to death4.017.15
Frequency of HFEs7.6510.59
Time to HFE0.570.24
KCCQ-TSS change from baseline (>=5-point difference)27.4835.91
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Asymptotic normal U statistics approach · p = 0.0027 (p-value for WR\<=1.0 (one-sided), variance calculated using the asymptotic normal U statistics approach.) · Stratified win ratio: 1.36 · 95% CI 1.09 to 1.68WR estimate= \[((a)+(c)+(e)+(g)) / ((b)+(d)+(f)+(h))\]
SecondaryNumber of Participants With Improvement of at Least 10 Points in KCCQ-TSS After 90 Days of Treatment

Number of participants with improvement of at least 10 points in Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS) from baseline after 90 days of treatment. The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire that includes 23 items that map to 7 domains: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life and self-efficacy. The symptom frequency and symptom burden domains are merged into the total symptom score. Scores are represented on a 0-to-100-point scale, where a higher score reflects a better health status.

Time frame:
At baseline and at day 90.
Reported as:
Count of participants · Participants
Number of Participants With Improvement of at Least 10 Points in KCCQ-TSS After 90 Days of Treatment
ParticipantsPlacebo10 mg Empagliflozin
Number of Participants With Improvement of at Least 10 Points in KCCQ-TSS After 90 Days of Treatment202220
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Regression, Logistic · p = 0.0970 (p-value for OR=1.0 (two-sided).) · Odds ratio (or): 1.522 · 95% CI 0.927 to 2.501Comparison vs. Placebo.
SecondaryChange From Baseline in KCCQ-TSS After 90 Days of Treatment

Change from baseline in Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS). The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire that includes 23 items that map to 7 domains: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life and self-efficacy. The symptom frequency and symptom burden domains are merged into the total symptom score. The score is represented on a 0-to-100-point scale, where a higher score reflects a better health status. Change from baseline in KCCQ-TSS at day 90 was modeled using a MMRM with visit (day 15 and day 30) as repeated measures, adjusted mean (standard error) after 90 days of treatment is reported.

Time frame:
At baseline, at day 15, 30 and at day 90.
Reported as:
Least squares mean · Score on a scale
Change From Baseline in KCCQ-TSS After 90 Days of Treatment
Score on a scalePlacebo10 mg Empagliflozin
Change From Baseline in KCCQ-TSS After 90 Days of Treatment31.73 ± 1.4936.19 ± 1.48
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Mixed Models Analysis · p = 0.0347 (p-value for difference = 0 (two-sided)) · Difference of adjusted mean: 4.45 · 95% CI 0.32 to 8.59
SecondaryChange From Baseline in Log-transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) Area Under the Curve (AUC) Over 30 Days of Treatment

Change from baseline in log-transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) Area under the curve (AUC) over 30 days of treatment is reported.

Time frame:
From baseline to day 30.
Reported as:
Geometric least squares mean · Picogram/milliliter * days
Change From Baseline in Log-transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) Area Under the Curve (AUC) Over 30 Days of Treatment
Picogram/milliliter * daysPlacebo10 mg Empagliflozin
Change From Baseline in Log-transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) Area Under the Curve (AUC) Over 30 Days of Treatment26.77 (25.15 to 28.48)24.07 (22.61 to 25.62)
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · ANCOVA · p = 0.0176 · Adjusted geometric mean ratio: 0.90 · 95% CI 0.82 to 0.98Comparison vs. Placebo
SecondaryPercentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 30 Days After Initial Hospital Discharge

The follow-up time for DAOH analyses was defined as 30 days after initial hospital discharge, or time between initial hospital discharge and date of censoring for non-fatal events except for patients who died within the first 30 days, where 30 days was considered as the DAOH follow-up time. DAOH for each patient was calculated as follow-up time subtracted by the number of days in hospital during the 30 days after initial hospital discharge as well as the number of days being dead within the 30 days. Percentage DAOH was defined as DAOH divided by the DAOH follow-up time of each patient multiplied by 100.

Time frame:
Up to 30 days after initial hospital discharge.
Reported as:
Mean · DAOH in percentage (%)
Percentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 30 Days After Initial Hospital Discharge
DAOH in percentage (%)Placebo10 mg Empagliflozin
Percentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 30 Days After Initial Hospital Discharge80.90 ± 21.2581.37 ± 18.62
SecondaryPercentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 90 Days After Randomisation

The follow-up time for DAOH analyses was defined as 90 days after randomisation, or time between randomisation and date of censoring for non-fatal events except for patients who died within the first 90 days, where 90 days was considered as the DAOH follow-up time. DAOH for each patient was calculated as follow-up time subtracted by the number of days in hospital during the 90 days after randomisation as well as the number of days being dead within the first 90 days. Percentage DAOH was defined as DAOH divided by the DAOH follow-up time of each patient multiplied by 100.

Time frame:
Up to 90 days after randomisation.
Reported as:
Mean · DAOH in percentage (%)
Percentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 90 Days After Randomisation
DAOH in percentage (%)Placebo10 mg Empagliflozin
Percentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 90 Days After Randomisation85.79 ± 22.7687.55 ± 19.54
SecondaryIncidence Rate of First Occurrence of Cardiovascular (CV) Death or Heart Failure Event (HFE) Until End of Trial Visit

Incidence rate of first occurrence of CV death or HFE until end of trial visit per 100 patient-year (pt-yrs) at risk is reported. Incidence rate per 100 pt-yrs = 100\* number of patients with event / time at risk \[years\].

Time frame:
Up to 127 days.
Reported as:
Number · Patients with events / 100pt-yrs at risk
Incidence Rate of First Occurrence of Cardiovascular (CV) Death or Heart Failure Event (HFE) Until End of Trial Visit
Patients with events / 100pt-yrs at riskPlacebo10 mg Empagliflozin
Incidence Rate of First Occurrence of Cardiovascular (CV) Death or Heart Failure Event (HFE) Until End of Trial Visit78.81 (58.11 to 102.62)55.01 (38.10 to 74.99)
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Regression, Cox · p = 0.1241 (p-value for HR=1.0 (two sided)) · Hazard ratio (hr): 0.71 · 95% CI 0.46 to 1.10Comparison vs. Placebo.
SecondaryNumber of Participants With Hospitalization for Heart Failure (HHF) Until 30 Days After Initial Hospital Discharge

Number of participants with hospitalization for heart failure (HHF) until 30 days after initial hospital discharge.

Time frame:
Up to 30 days after initial hospital discharge.
Reported as:
Count of participants · Participants
Number of Participants With Hospitalization for Heart Failure (HHF) Until 30 Days After Initial Hospital Discharge
ParticipantsPlacebo10 mg Empagliflozin
Number of Participants With Hospitalization for Heart Failure (HHF) Until 30 Days After Initial Hospital Discharge1214
SecondaryComposite Renal Endpoint: Number of Participants With Chronic Dialysis, Renal Transplant, Sustained Reduction in eGFR(CKD-EPI)cr

The occurrence of the composite renal endpoint: * chronic dialysis (with a frequency of twice per week or more for at least 90 days), or * renal transplant, or * sustained reduction in Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) from baseline of ≥40%, or * sustained eGFR \[mL/min/1.73 m2\] \<15 and baseline value ≥30, or * sustained eGFR \<10 and baseline value \<30; is reported by number of participants with component events. (These events may have occurred after the endpoint was already met. Combinations may not have occurred on the same day). Sustained was determined by 2 or more consecutive post-baseline central laboratory measurements separated by at least 30 days.

Time frame:
Up to 90 days.
Reported as:
Count of participants · Participants
Composite Renal Endpoint: Number of Participants With Chronic Dialysis, Renal Transplant, Sustained Reduction in eGFR(CKD-EPI)cr
ParticipantsPlacebo10 mg Empagliflozin
Composite Renal Endpoint: Number of Participants With Chronic Dialysis, Renal Transplant, Sustained Reduction in eGFR(CKD-EPI)cr20
SecondaryWeight Change Per Mean Daily Loop Diuretic Dose After 15 Days of Treatment

Diuretic effect as assessed by weight change per mean daily loop diuretic dose after 15 days of treatment. Diuretic dose = 40 mg intravenous furosemide or 80 mg oral furosemide. Abbreviation: Kg: Kilogram

Time frame:
At baseline and at day 15.
Reported as:
Mean · Kg per loop diuretic dose
Weight Change Per Mean Daily Loop Diuretic Dose After 15 Days of Treatment
Kg per loop diuretic dosePlacebo10 mg Empagliflozin
Weight Change Per Mean Daily Loop Diuretic Dose After 15 Days of Treatment-2.43 ± 23.46-4.45 ± 16.65
SecondaryWeight Change Per Mean Daily Loop Diuretic Dose After 30 Days of Treatment

Diuretic effect as assessed by weight change per mean daily loop diuretic dose after 30 days of treatment. Diuretic dose = 40 mg intravenous furosemide or 80 mg oral furosemide Abbreviation: Kg: Kilogram

Time frame:
At baseline and at day 30.
Reported as:
Mean · Kg per loop diuretic dose
Weight Change Per Mean Daily Loop Diuretic Dose After 30 Days of Treatment
Kg per loop diuretic dosePlacebo10 mg Empagliflozin
Weight Change Per Mean Daily Loop Diuretic Dose After 30 Days of Treatment-2.69 ± 21.74-6.91 ± 25.34

Adverse events

Collected over [All-cause Mortality]: From first study drug intake until end of follow-up, up to 202 days. [Serious and Other Adverse Event]: From first study drug intake until 7 days after last intake of study medication, up to 127 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo22/265 (8.3%)115/264 (43.6%)19/264 (7.2%)
10 mg Empagliflozin11/265 (4.2%)84/260 (32.3%)20/260 (7.7%)
Most frequent serious events
Showing 10 of 144
Most frequent serious events
EventPlacebo10 mg Empagliflozin
Cardiac failureCardiac disorders37/26425/260
Acute kidney injuryRenal and urinary disorders19/26410/260
Cardiac failure congestiveCardiac disorders11/2642/260
Ventricular tachycardiaCardiac disorders7/2648/260
Cardiac arrestCardiac disorders5/2642/260
HypotensionVascular disorders5/2642/260
PneumoniaInfections and infestations4/2640/260
Renal impairmentRenal and urinary disorders4/2642/260
Atrial fibrillationCardiac disorders2/2643/260
BradycardiaCardiac disorders0/2643/260
Most frequent other events
Most frequent other events
EventPlacebo10 mg Empagliflozin
HypotensionVascular disorders19/26420/260

Baseline characteristics

Randomised Set (RS), including all randomised patients.

Age, Continuous
Age, Continuous(Years)Placebo10 mg EmpagliflozinTotal
Mean68.1 ± 13.868.9 ± 12.668.5 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Placebo10 mg EmpagliflozinTotal
Female9386179
Male172179351
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo10 mg EmpagliflozinTotal
Hispanic or Latino9615
Not Hispanic or Latino256259515
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo10 mg EmpagliflozinTotal
American Indian or Alaska Native202
Asian253257
Native Hawaiian or Other Pacific Islander000
Black or African American332154
White202211413
More than one race213
Unknown or Not Reported101
Kansas City cardiomyopathy questionnaire-Total symptom score (KCCQ-TSS)
Kansas City cardiomyopathy questionnaire-Total symptom score (KCCQ-TSS)(Score on a scale)Placebo10 mg EmpagliflozinTotal
Mean41.91 ± 23.9839.71 ± 24.0640.81 ± 24.02
08

Study locations

118 sites
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California Irvine
    Orange, California 92865, United States
  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Cardiology Associates Research Co.
    Daytona Beach, Florida 32117, United States
  • University of Florida Health Jacksonville
    Jacksonville, Florida 32209, United States
  • Grady Memorial Hospital
    Atlanta, Georgia 30303, United States
  • Methodist Medical Center
    Peoria, Illinois 61603, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • United Hospital
    Saint Paul, Minnesota 55102, United States
  • University Of Mississippi Medical Center
    Jackson, Mississippi 39216-4505, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Cardiovascular Associates of the Delaware Valley
    Elmer, New Jersey 08318, United States
  • Jefferson Washington Township Hospital
    Washington Township, New Jersey 08080, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Erie County Medical Center
    Buffalo, New York 14215, United States
  • The DeMatteis Center for Cardiac Research and Education
    Greenvale, New York 11548, United States
  • Stony Brook Medicine
    Stony Brook, New York 11794, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • North Carolina Heart and Vascular
    Raleigh, North Carolina 27607, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • South Oklahoma Heart Research Group
    Oklahoma City, Oklahoma 73135, United States
  • Ralph H. Johnson VA Medical Center
    Charleston, South Carolina 29401, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Pharmatex Research
    Amarillo, Texas 79109, United States
  • Center for Advanced Cardiac Care - Heart Failure Clinic
    Plano, Texas 75093, United States
  • Inova Fairfax Medical Campus
    Falls Church, Virginia 22042, United States
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Aalst - HOSP Onze-Lieve-Vrouw
    Aalst, 9300, Belgium
  • Brussels - UNIV UZ Brussel
    Brussel, 1090, Belgium
  • AZ Sint-Blasius
    Dendermonde, 9200, Belgium
  • Ziekenhuis Oost-Limburg - Campus Sint-Jan
    Genk, 3600, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Liège - HOSP CHR de la Citadelle
    Liège, 4000, Belgium
  • UNIV Ambroise Paré
    Mons, 7000, Belgium
  • Royal Jubilee Hospital
    Victoria, British Columbia V8R 1J8, Canada
  • St. Boniface General Hospital
    Winnipeg, Manitoba R2H 2A6, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Beijing Chao-Yang Hospital
    Beijing, 100020, China
  • Beijing AnZhen Hospital
    Beijing, 100029, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • West China Hospital
    Chengdu, 610041, China
  • Xiamen Cardiovascular Hospital Xiamen University
    Xiamen, 361004, China
  • First Affiliated Hospital of Xi'an JiaoTong University
    Xian, 710061, China
  • University Hospital Brno
    Brno, 639 00, Czechia
  • Univ.Hosp U Svate Anny, I.Internal Clinic-Cardiology,Brno
    Brno, 65691, Czechia
  • University Hospital Motol
    Prag, 15006, Czechia
  • District Hospital, Tabor
    Tabor, 390 03, Czechia
  • Aalborg Universitetsshospital
    Aalborg, 9000, Denmark
  • Frederiksberg Hospital
    Frederiksberg, 2000, Denmark
  • Herlev and Gentofte Hospital
    Herlev, 2733, Denmark
  • Hvidovre Hospital
    Hvidovre, 2650, Denmark
  • Viborg Regionhospital
    Viborg, 8800, Denmark
  • Charité - Universitätsmedizin Berlin
    Berlin, 12203, Germany
  • Bremer Institut für Herz- und Kreislaufforschung (BIHKF) am Klinikum Links der Weser
    Bremen, 28277, Germany
  • Herzzentrum Dresden GmbH Universitätsklinik
    Dresden, 01307, Germany
  • Universitäts-Herzzentrum Freiburg, Bad Krozingen GmbH
    Freiburg, 79106, Germany
  • Universitätsklinikum Gießen und Marburg GmbH
    Gießen, 35392, Germany
  • Universitätsklinikum Jena
    Jena, 07743, Germany
  • Asklepios Klinik Langen-Seligenstadt GmbH
    Langen, 63225, Germany
  • Klinikum Leverkusen gGmbH, Leverkusen
    Leverkusen, 51375, Germany
  • Klinikum der Stadt Ludwigshafen am Rhein gGmbH
    Ludwigshafen, 67063, Germany
  • Universitätsklinikum Schleswig-Holstein, Campus Lübeck
    Lübeck, 23538, Germany
  • Universitätsklinikum Würzburg AÖR
    Würzburg, 97080, Germany
  • Semmelweis University
    Budapest, 1088, Hungary
  • University Debrecen Hospital
    Debrecen, 4032, Hungary
  • University of Pecs
    Pecs, 7624, Hungary
  • Fejer County Saint George University Teaching Hospital
    Szekesfehervar, 8000, Hungary
  • Csongrad Country Dr Bugyi Istvan Hosp.
    Szentes, 6600, Hungary
  • ASST degli Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Università degli Studi "Magna Grecia" - Campus "S. Venuta"
    Catanzaro, 88100, Italy
  • Ospedale della Val di Chiana Santa Margherita
    Cortona, 52040, Italy
  • Az.Osp. Universitaria "Ospedali Riuniti"
    Foggia, 71100, Italy
  • Centro Cardiologico Monzino-IRCCS
    Milano, 20138, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • Osp. Guglielmo da Saliceto AUSL di Piacenza
    Piacenza, 29121, Italy
  • IRCCS San Raffaele
    Roma, 00163, Italy
  • AO Città della Salute e della
    Torino, 10126, Italy
  • Azienda Sanitaria Universitaria Giuliano Isontina
    Trieste, 34124, Italy
  • Japan Community Health Care Organization Kyushu Hospital
    Fukuoka, Kitakyushu, 806-8501, Japan
  • Mito Medical Center
    Ibaraki, Higashiibaraki-gun, 311-3193, Japan
  • Kanagawa Cardiovascular and Respiratory Center
    Kanagawa, Yokohama, 236-0051, Japan
  • Shinshu University Hospital
    Nagano, Matsumoto, 390-8621, Japan
  • The Sakakibara Heart Institute of Okayama
    Okayama, Okayama, 700-0804, Japan
  • Osaka University Hospital
    Osaka, Suita, 565-0871, Japan
  • Kawaguchi Cardiovascular and Respiratory Hospital
    Saitama, Kawaguchi, 333-0842, Japan
  • Saitama Sekishikai Hospital
    Saitama, Sayama, 350-1305, Japan
  • Nihon University Itabashi Hospital
    Tokyo, Itabashi-ku, 173-8610, Japan
  • Jeroen Bosch Ziekenhuis-Hertogenbosch
    's HERTOGENBOSCH, 5223 GZ, Netherlands
  • Gelre Ziekenhuizen Apeldoorn
    Apeldoorn, 7334 DZ, Netherlands
  • HagaZiekenhuis
    Den Haag, 2545 AA, Netherlands
  • TREANT Zorggroep
    Emmen, 7824 AA, Netherlands
  • Groene Hart ziekenhuis
    Gouda, 2803 HH, Netherlands
  • Universitair Medisch Centrum Groningen
    Groningen, 9713 GZ, Netherlands
  • Sint Jansdal Ziekenhuis
    Harderwijk, 3844 DG, Netherlands
  • Alrijne Leiderdorp
    Leiderdorp, 2353 GA, Netherlands
  • Bravis ziekenhuis, locatie Roosendaal
    Roosendaal, 4708 AE, Netherlands
  • Diakonessenhuis Utrecht
    Utrecht, 3582 KE, Netherlands

Showing the first 100 of 118 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, Comin-Colet J, Ferreira JP, Mentz RJ, Nassif ME, Psotka MA, Tromp J, Brueckmann M, Blatchford JP, Salsali A, Voors AA. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation. 2022 Jul 26;146(4):279-288. doi: 10.1161/CIRCULATIONAHA.122.059725. Epub 2022 Apr 4. PubMed 35377706 ↗
  • Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. PubMed 35228754 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in May 2021, 12 months.

Results were first posted in Jun 2022, 1 year after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 12 months is below that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2019
First posted
Nov 8, 2019
StartActual
May 18, 2020
Primary completionActual
May 28, 2021
CompletionActual
Jun 2, 2021
Results first posted
Jun 6, 2022
Last update
Jul 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04157751
Responsible party
Sponsor
First posted
Nov 8, 2019
Start date
May 18, 2020
Primary completion
May 28, 2021
Completion
Jun 2, 2021
Results posted
Jun 6, 2022
Last update
Jul 19, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion